Cargando…
SARS-CoV-2 BA.1 variant is neutralized by vaccine booster-elicited serum, but evades most convalescent serum and therapeutic antibodies
The rapid spread of the highly contagious Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) along with its high number of mutations in the spike gene has raised alarms about the effectiveness of current medical countermeasures. To address this concern, we measured neutr...
Autores principales: | Lusvarghi, Sabrina, Pollett, Simon D., Neerukonda, Sabari Nath, Wang, Wei, Wang, Richard, Vassell, Russell, Epsi, Nusrat J., Fries, Anthony C., Agan, Brian K., Lindholm, David A., Colombo, Christopher J., Mody, Rupal, Ewers, Evan C., Lalani, Tahaniyat, Ganesan, Anuradha, Goguet, Emilie, Hollis-Perry, Monique, Coggins, Si’Ana A., Simons, Mark P., Katzelnick, Leah C., Wang, Gregory, Tribble, David R., Bentley, Lisa, Eakin, Ann E., Broder, Christopher C., Erlandson, Karl J., Laing, Eric D., Burgess, Timothy H., Mitre, Edward, Weiss, Carol D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for the Advancement of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8995032/ https://www.ncbi.nlm.nih.gov/pubmed/35380448 http://dx.doi.org/10.1126/scitranslmed.abn8543 |
Ejemplares similares
-
SARS-CoV-2 Omicron neutralization by therapeutic antibodies, convalescent sera, and post-mRNA vaccine booster
por: Lusvarghi, Sabrina, et al.
Publicado: (2021) -
SARS-CoV-2 Delta Variant Displays Moderate Resistance to Neutralizing Antibodies and Spike Protein Properties of Higher Soluble ACE2 Sensitivity, Enhanced Cleavage and Fusogenic Activity
por: Neerukonda, Sabari Nath, et al.
Publicado: (2021) -
Key Substitutions in the Spike Protein of SARS-CoV-2 Variants Can Predict Resistance to Monoclonal Antibodies, but Other Substitutions Can Modify the Effects
por: Lusvarghi, Sabrina, et al.
Publicado: (2022) -
Antigenic cartography of well-characterized human sera shows SARS-CoV-2 neutralization differences based on infection and vaccination history
por: Wang, Wei, et al.
Publicado: (2022) -
Characterization of Entry Pathways, Species-Specific Angiotensin-Converting Enzyme 2 Residues Determining Entry, and Antibody Neutralization Evasion of Omicron BA.1, BA.1.1, BA.2, and BA.3 Variants
por: Neerukonda, Sabari Nath, et al.
Publicado: (2022)